摘要
目的:探讨低分子肝素钙联合前列地尔治疗慢性肺源性心脏病心力衰竭的临床效果。方法:收治慢性肺源性心脏病急性加重期心力衰竭患者40例,随机分为对照组和观察组,前者采用常规治疗法,后者在此基础上,加用低分子肝素钙联合前列地尔治疗,比较两组患者凝血功能、心功能指标、血液黏滞度及治疗有效率。结果:治疗后,患者BNP、CK-MB、LDH、ALT、AST、BUN、Cr指标均下降,其中前5个指标与治疗前相比,差异具有统计学意义(P<0.05)。治疗后患者血细胞比容(0.41±0.07)与治疗前相比(0.49±0.09),差异具有统计学意义(P<0.05)。对照组和观察组患者治疗总有效率分别为90.0%和100.0%,后者明显高于前者,差异具有统计学意义(P<0.05)。两组患者均未出现严重不良反应。结论:低分子肝素钙联合前列地尔治疗慢性肺源性心脏病心力衰竭临床效果较优,对患者凝血功能无影响。
Objective:To investigate the clinical effect of low molecular weight heparin calcium combined with alprostadil in the treatment of chronic pulmonary heart disease with heart failure.Methods:40 patients with chronic pulmonary heart disease in acute exacerbation of heart failure were randomly divided into the control group and the observation group.The former used conventional therapy,on this basis,the latter used low molecular weight heparin calcium combined with alprostadil treatment.The coagulation function,cardiac function index,blood viscosity and treatment efficiency were compared between groups.Results:After treatment,patients with BNP、CK-MB、LDH、ALT、AST、BUN、Cr indicators were decreased,and the first 5 indicators compared with before treatment,with statistical difference(P<0.05).After treatment,the hematocrit was(0.41 ± 0.07),compared with before treatment(0.49 ± 0.09),the difference was statistically significant(P<0.05).The total effective rate of the control group and the observation group were 90% and 100%,respectively,and the latter was obviously higher than the former,with statistical difference(P<0.05).There were no serious adverse reactions found in the patients.Conclusion:Low molecular weight heparin calcium combined with alprostadil in the treatment of chronic pulmonary heart disease with heart failure has better clinical effect,and it has no effect on the coagulation function of patients.
出处
《中国社区医师》
2017年第18期53-54,共2页
Chinese Community Doctors
关键词
低分子肝素钙
前列地尔
慢性肺源性心脏病
心力衰竭
Low molecular weight heparin calcium
Alprostadil
Chronic pulmonary heart disease
Heart failure
